Supporter
上海张江金山高科技产业开发有限公司是由张江药谷和上海湾区高新区共同出资设立的园区平台公司，是践行“张江研发、上海制造”的最早尝试，所运营的“金准园”、“金创园”两个片区约11万平米厂房物业内，承接和吸引20余家优质生物医药企业和机构入驻。初步形成了包括科济制药、恒润达生等在内的CGT产业化加速营和以上海实验动物研究中心平台为核心的实验动物城两大主要集群。
2024年，公司以“金创园二期”项目的建设吹响新一轮发展号角，并全新推出张江鑫药园（ZhangJiang ATMP Industrial Park）的品牌。项目将于2026年建成，新增的8万平米生物医药专业化厂房物业迭代产品，将继续履行“张江研发、上海制造”的使命，承接更多民族创新医药产业化项目。
竭诚欢迎有识之士前来参观考察，投资兴业！
招商热线：021-57272225
Shanghai Zhangjiang Jinshan High tech Industrial Development Co., Ltd. is a park platform company jointly established by Zhangjiang Pharmaceutical Valley and Shanghai Bay Area High tech Zone. It is the earliest attempt to implement "Zhangjiang R&D, Shanghai Manufacturing". The company operates approximately 110000 square meters of factory properties in the "Jinzhun Park" and "Jinchuang Park" areas, and has undertaken and attracted more than 20 high-quality biopharmaceutical enterprises and institutions to settle in. Two main clusters have initially formed, namely CGT Industrialization Acceleration Camp including Keji Pharmaceutical and Hengrun Dasheng, and Experimental Animal City centered on the Shanghai Experimental Animal Research Center platform.
In 2024, the company sounded the horn of a new round of development with the construction of the "Jinchuang Park Phase II" project and launched the brand of ZhangJiang ATMP Industrial Park. The project is expected to be completed in 2026, with an additional 80000 square meters of specialized biopharmaceutical factory and iterative products. It will continue to fulfill the mission of "Zhangjiang R&D, Shanghai Manufacturing" and undertake more national innovative pharmaceutical industrialization projects.
Sincerely welcome knowledgeable people to visit, inspect, invest and develop!
Investment Hotline: 021-5727225
2024年，公司以“金创园二期”项目的建设吹响新一轮发展号角，并全新推出张江鑫药园（ZhangJiang ATMP Industrial Park）的品牌。项目将于2026年建成，新增的8万平米生物医药专业化厂房物业迭代产品，将继续履行“张江研发、上海制造”的使命，承接更多民族创新医药产业化项目。
竭诚欢迎有识之士前来参观考察，投资兴业！
招商热线：021-57272225
Shanghai Zhangjiang Jinshan High tech Industrial Development Co., Ltd. is a park platform company jointly established by Zhangjiang Pharmaceutical Valley and Shanghai Bay Area High tech Zone. It is the earliest attempt to implement "Zhangjiang R&D, Shanghai Manufacturing". The company operates approximately 110000 square meters of factory properties in the "Jinzhun Park" and "Jinchuang Park" areas, and has undertaken and attracted more than 20 high-quality biopharmaceutical enterprises and institutions to settle in. Two main clusters have initially formed, namely CGT Industrialization Acceleration Camp including Keji Pharmaceutical and Hengrun Dasheng, and Experimental Animal City centered on the Shanghai Experimental Animal Research Center platform.
In 2024, the company sounded the horn of a new round of development with the construction of the "Jinchuang Park Phase II" project and launched the brand of ZhangJiang ATMP Industrial Park. The project is expected to be completed in 2026, with an additional 80000 square meters of specialized biopharmaceutical factory and iterative products. It will continue to fulfill the mission of "Zhangjiang R&D, Shanghai Manufacturing" and undertake more national innovative pharmaceutical industrialization projects.
Sincerely welcome knowledgeable people to visit, inspect, invest and develop!
Investment Hotline: 021-5727225
The BayHelix Group is a non-profit professional organization of business leaders with a mission to shape the growth of the life sciences and healthcare industry. Founded in 2001 in the San Francisco Bay Area, BayHelix has grown to over 800 members globally with a strong presence in China and the US. BayHelix aspires to foster and create business opportunities, supply and nurture leaders for the community, and network and share information and experience among its members.
The diverse membership base covers many of the world’s top pharmaceutical and biopharmaceutical companies, leading professional services and investment firms, as well as start-up biotech companies in China and the US. BayHelix membership is by-invitation only. Over two thirds of members are C-level executives. The majority of them are cross trained in science and business as well as bilingual in Chinese and English. BayHelix has become an influential organization that connects emerging biopharmaceutical companies in China to their counterparts around the world.
https://bayhelix.org/
The diverse membership base covers many of the world’s top pharmaceutical and biopharmaceutical companies, leading professional services and investment firms, as well as start-up biotech companies in China and the US. BayHelix membership is by-invitation only. Over two thirds of members are C-level executives. The majority of them are cross trained in science and business as well as bilingual in Chinese and English. BayHelix has become an influential organization that connects emerging biopharmaceutical companies in China to their counterparts around the world.
https://bayhelix.org/
eChinaHealth is a new business of eChinaChem in the field of medical health which is China's leading pharmaceutical and chemical B2B company. In 2019, eChinaHealth and the American Society of Clinical Oncology (ASCO) signed the exclusive agency rights for ASCO official journals and magazines in Greater China, including the Journal of Clinical Oncology (JCO), Academic and business journals such as Journal of Oncology Practice (JOP), The ASCO Post (The ASCO Post), and more.
The ASCO Global Conference Abstracts and Data are the sole responsibility and operation by the Doctor Evidence (DRE) platform of the physician evidence company. eChinaHealth also signed the exclusive China agent for the DRE platform. Oncologists can use this AI-enabled platform to conduct in-depth queries on ASCO and other medical literature data, including advanced terminology search, concept identification, author analysis, and timeline analysis of authors' associations with other published literature. Advanced search capabilities allow users to search for comparisons and analyses across all calendar summaries, and present results and trends. The DRE platform includes summaries and data of all ASCO conferences over the past 20 years, enabling R & D personnel to track R & D trends and conduct longitudinal analysis and investigation of evolving data.
http://www.echinahealth.com/
The ASCO Global Conference Abstracts and Data are the sole responsibility and operation by the Doctor Evidence (DRE) platform of the physician evidence company. eChinaHealth also signed the exclusive China agent for the DRE platform. Oncologists can use this AI-enabled platform to conduct in-depth queries on ASCO and other medical literature data, including advanced terminology search, concept identification, author analysis, and timeline analysis of authors' associations with other published literature. Advanced search capabilities allow users to search for comparisons and analyses across all calendar summaries, and present results and trends. The DRE platform includes summaries and data of all ASCO conferences over the past 20 years, enabling R & D personnel to track R & D trends and conduct longitudinal analysis and investigation of evolving data.
http://www.echinahealth.com/
CBA is an independent, non-political, not-for-profit professional organization led by its board of directors and executive committees. Currently, CBA has over 3000 registered individual members. Most of its members are from universities, research institutions, biopharmaceutical companies, law firms, venture capital firms, and government agencies. Over 80 percent of the CBA members have doctoral degrees.
CBA has grown to be a truly international organization, with members residing in the U.S., China, Europe, Canada, Singapore, Japan, Australia, and other countries and regions. CBA’s mission is to promote career advancement and collaboration among Chinese-American biopharmaceutical professionals, and to promote technology transfer and entrepreneurship, especially between the U.S. and China, as well as countries and regions in the Pacific Rim. Since its inception in 1995, CBA has been playing a prominent role in the Chinese and U.S. biopharmaceutical industries. Every year, CBA organizes a number of specially designed workshops, seminars, meetings, and networking events in both China and the U.S. To learn more about CBA, please visit
www.cba-usa.org.
CBA has grown to be a truly international organization, with members residing in the U.S., China, Europe, Canada, Singapore, Japan, Australia, and other countries and regions. CBA’s mission is to promote career advancement and collaboration among Chinese-American biopharmaceutical professionals, and to promote technology transfer and entrepreneurship, especially between the U.S. and China, as well as countries and regions in the Pacific Rim. Since its inception in 1995, CBA has been playing a prominent role in the Chinese and U.S. biopharmaceutical industries. Every year, CBA organizes a number of specially designed workshops, seminars, meetings, and networking events in both China and the U.S. To learn more about CBA, please visit
www.cba-usa.org.
Sino-American Pharmaceutical Professionals Association - Greater Philadelphia (SAPA-GP) is a non-profit (501(c)(3)) professional organization founded in 2002 (www.sapa-gp.org). We strive to serve the rapidly growing pharmaceutical professional community in the Greater Philadelphia area. The Greater Philadelphia area is one of the major hubs for global pharmaceutical companies (e.g. BMS, GSK, Johnson & Johnson, Merck, Pfizer, Teva), biotech companies (e.g. Alliance Pharma, Frontage Laboratories, PuraCap, Shire) and academic institutions (e.g. University of Pennsylvania, Thomas Jefferson University, Temple University, Drexel University, Rowan University, Villanova University). Over past decades, SAPA-GP has established a broad member base and become the premier organization in the region for bridging the pharmaceutical and healthcare industries of China and the US.
Our Missions
• To promote pharmaceutical sciences and biotechnology
• To contribute to public health education by raising public awareness
• To facilitate scientific and business cooperation between US and China
• To foster career development of pharmaceutical professionals
Our members consist of
• Scientists, clinicians, and executives from pharmaceutical and biotech companies
• Students and postdoctoral fellows from academic institutions and universities
• Business and thought leaders from financial institutions and healthcare industries
Our Events
• Annual conference
• Scientific symposiums and webinars
• Business development workshops
• Career development workshops & Job fairs
• Professional training
www.cba-usa.org.
Our Missions
• To promote pharmaceutical sciences and biotechnology
• To contribute to public health education by raising public awareness
• To facilitate scientific and business cooperation between US and China
• To foster career development of pharmaceutical professionals
Our members consist of
• Scientists, clinicians, and executives from pharmaceutical and biotech companies
• Students and postdoctoral fellows from academic institutions and universities
• Business and thought leaders from financial institutions and healthcare industries
Our Events
• Annual conference
• Scientific symposiums and webinars
• Business development workshops
• Career development workshops & Job fairs
• Professional training
www.cba-usa.org.
AAIH is a not-for-profit (501(c)(4)) founded in 2018 and formally launching in January 2019 (https://theaaih.org/). We are a global advocacy organization for the advancement and use of AI/ Machine Learning in healthcare to improve patients’ lives and create more efficient, sustainable, and accessible healthcare systems. Through investment, invention, and innovation in AI, the AAIH and our member organizations are creating novel interventions and product solutions that reduce failure rates and costs while improving quality across the entire healthcare spectrum. AAIH is a diverse member base that includes dedicated healthcare AI companies and organizations, as well as, those utilizing AI platforms for biomedical discovery, clinical research, diagnostics and devices, and precision medicine.
https://theaaih.org/
https://theaaih.org/
\
